Get Started
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Gene Transfection Kits for Primary Cells
• Up to 95% cell transfection efficiency
• No observed toxicity
• Same reagents in vitro and in vivo
• Easy to use with NanoAssemblr™ technology
• Non-viral transfection
Cell Types:
• Primary Neurons, Astrocytes, and mixed cultures
• iPS derived cells
• Hepatocytes
Nucleic Acids:
• Short interfering RNA (siRNA)
• Messenger RNA (mRNA)
• Plasmid DNA (pDNA)
Transfection Kits
Adapted from RNAi therapeutic technology currently in clinical trials, Precision NanoSystems’ non-viral gene transfection kits perform exceptionally well in cell types that are challenging to transfect with other methods (eg. transfection of primary cells). This technology encapsulates nucleic acids in lipid nanoparticles (LNPs) that mimic low-density lipoproteins (LDLs). LNPs take advantage of an endogenous pathway ubiquitous among mammalian cells to achieve high transfection efficiency (typically >90%) with no observable toxicity. Kits for use with different cell types and nucleic acid payloads including siRNA, messenger RNA (mRNA), and plasmid DNA (pDNA) are available. The kits are designed for use with NanoAssemblr™ systems established in the drug formulation and nanoparticle manufacturing field for ensuring high-quality reproducible results are achieved rapidly with minimal training.
• No observed toxicity
• Same reagents in vitro and in vivo
• Easy to use with NanoAssemblr™ technology
• Non-viral transfection
Cell Types:
• Primary Neurons, Astrocytes, and mixed cultures
• iPS derived cells
• Hepatocytes
Nucleic Acids:
• Short interfering RNA (siRNA)
• Messenger RNA (mRNA)
• Plasmid DNA (pDNA)
Transfection Kits
Adapted from RNAi therapeutic technology currently in clinical trials, Precision NanoSystems’ non-viral gene transfection kits perform exceptionally well in cell types that are challenging to transfect with other methods (eg. transfection of primary cells). This technology encapsulates nucleic acids in lipid nanoparticles (LNPs) that mimic low-density lipoproteins (LDLs). LNPs take advantage of an endogenous pathway ubiquitous among mammalian cells to achieve high transfection efficiency (typically >90%) with no observable toxicity. Kits for use with different cell types and nucleic acid payloads including siRNA, messenger RNA (mRNA), and plasmid DNA (pDNA) are available. The kits are designed for use with NanoAssemblr™ systems established in the drug formulation and nanoparticle manufacturing field for ensuring high-quality reproducible results are achieved rapidly with minimal training.
Above Left: Primary rat neurons expressing GFP 48h after cell transfection with Neuro9-mRNA. Above Right: Primary rat neurons expressing GFP 48h following transfection with Neuro9-pDNA. Bottom: Rendition of the endogenous uptake pathway used by Precision NanoSystems’ transfection reagents to deliver nucleic acids in a non-toxic way.
Simple workflow for Spark Transfection Kit
Simple workflow for NanoAssemblr® Benchtop Transfection Kit
Resource Center
Publication - Summary
April 04, 2019
The Journal of Neuroscience
PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease
Read MorePublication - Summary
February 07, 2019
Nano Research
Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...
Read MoreApplication Note
January 16, 2019
mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials
Read More
Publication - Summary
September 24, 2018
Nucleic Acid Therapeutics
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Read MorePoster
July 01, 2018
Publication - Summary
February 27, 2018
Cell Reports
A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
Read More
MENU
